 Aeterna Zentaris Inc. AEZS AEZS the Company, a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the closing of its previously announced public offering of 17,544,516 units at a price to the public of 0.45 per unit and 9,122,150 pre-funded units at a price to the public of 0.4499 per pre-funded unit. Each unit sold in this offering contains one common share and one common warrant to purchase one common share. Each pre-funded unit sold in this offering contains one pre-funded warrant to purchase one common share at an exercise price of 0.0001 per share and one common warrant to purchase one common share. 